Image_1_IL-27 Counteracts Neuropathic Pain Development Through Induction of IL-10.TIF (587.06 kB)

Image_1_IL-27 Counteracts Neuropathic Pain Development Through Induction of IL-10.TIF

Download (587.06 kB)
posted on 2020-01-28, 04:28 authored by Miriam M. Fonseca, Marcela Davoli-Ferreira, Flávia Santa-Cecília, Rafaela M. Guimarães, Francisco F. B. Oliveira, Ricardo Kusuda, David W. Ferreira, José C. Alves-Filho, Fernando Q. Cunha, Thiago M. Cunha

Neuroimmune–glia interactions have been implicated in the development of neuropathic pain. Interleukin-27 (IL-27) is a cytokine that presents regulatory activity in inflammatory conditions of the central nervous system. Thus, we hypothesized that IL-27 would participate in the neuropathic pain process. Here, we found that neuropathic pain caused by peripheral nerve injury (spared nerve injury model; SNI), was enhanced in IL-27-deficient(−/−) mice, whereas nociceptive pain is similar to that of wild-type mice. SNI induced an increase in the expression of IL-27 and its receptor subunit (Wsx1) in the sensory ganglia and spinal cord. IL-27 receptor was expressed mainly in resident macrophage, microglia, and astrocytes of the sensory ganglia and spinal cord, respectively. Finally, we identify that the antinociceptive effect of IL-27 was not observed in IL-10−/− mice. These results provided evidence that IL-27 is a cytokine produced after peripheral nerve injury that counteracts neuropathic pain development through induction of the antinociceptive cytokine IL-10. In summary, our study unraveled the role of IL-27 as a regulatory cytokine that counteracts the development of neuropathic pain after peripheral nerve damage. In conclusion, they indicate that immunotherapies based on IL-27 could emerge as possible therapeutic approaches for the prevention of neuropathic pain development after peripheral nerve injury.